{"id": "1357355410550882309", "creation": 1612453722.0, "user_id": "1233901069366771712", "social_network": "twitter", "nsfw": false, "request": ["b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc"], "metrics": {"b26b9dbc-1c5a-4cd3-a3a6-c2f5a51ad0fc": {"retweet_count": 0, "reply_count": 0, "like_count": 1, "quote_count": 0}}, "text": ".@Vaxart Tanks 58% On Disappointing Oral #COVID19 #vaccine Trial Results\n\nAll is not lost, VXA-CoV2-1 could have broad activity against existing and future #coronavirus strains,\u201d said $VXRT CEO Andrei Floroiu.\n\n$TBIO $SRNE $ARCT $ATRA #StocksInFocus\n\nhttps://t.co/p2FHBFNrUE", "first_save": 1634559108.199414, "hashtags": ["#COVID19", "#VACCINE", "#CORONAVIRUS", "#STOCKSINFOCUS"]}